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Uterine leiomyomas are the most common benign gynecologic tumors. To date laparoscopy
myomectomy is the gold standard for treatment of symptomatic fibroids in reproductive-
aged women. Detailed counseling about the effects of this procedure on postoperative sexu-
ality and quality of life is important in these patients. However, available data on these sub-
jects are limited and contradictory. The aim of this study was to assess sexual function and
quality of life in premenopausal women undergoing laparoscopic myomectomy for symp-
tomatic uterine fibroids.
Material and Methods
All premenopausal women who underwent laparoscopic myomectomy for symptomatic
fibroids between April 2012 and August 2014 at a tertiary university center were enrolled
in this prospective observational cohort study. Sexual function and quality of life were
assessed for the pre- and postoperative (six months post-operatively) state using two vali-
dated questionnaires, the Female Sexual Function Index (FSFI) and the European Quality
of Life Five-Dimension Scale (EQ-5D).
Results
Ninety-five of the 115 (83%) eligible patients completed the study. Overall a significant
improvement in quality of life and sexual function was observed in the study cohort: Median
FSFI (28 (18.7–35.2)) and EQ-5D scores (1 (0.61–1) after laparoscopic myomectomy were
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significantly higher than preoperative scores (21.2 (5.2–33.5); 0.9 (0.2–1); p 0.01). The
number, position and localization of the largest fibroids were not correlated with pre- or post-
operative sexual function or quality of life.
Conclusion
Laparoscopic myomectomy might have positive short-term effects on postoperative quality
of life and sexual function in premenopausal women suffering from symptomatic fibroids.
Introduction
Uterine leiomyomas are the most common benign gynecologic tumors [1], with an 80% inci-
dence [2, 3] and clinical appearance in approximately 25% of reproductive-aged women [4].
Symptoms (e.g. bleeding disorders, pelvic pressure/pain, reproductive dysfunction) [5, 6] cor-
relate with fibroid number, size, position, localization and degenerative changes of fibroids [7]
and can affect patients‘quality of life and sexual function [8, 9]. Despite the recent introduction
of pharmacological and radiologic interventional approaches, surgery (laparoscopic myomec-
tomy or conventional myomectomy via laparotomy) remains one of the main treatment
options of symptomatic fibroids in reproductive-aged women [6, 10]. Patient-reported
parameters (i.e. postoperative quality of life and sexual function) may be used to assess treat-
ment outcomes, supplementing traditionally used peri- and postoperative parameters (e.g.
complication rates, blood loss, duration of surgery) which correlate insufficiently with treat-
ment success in terms of symptom reduction [9, 11]. Few studies have evaluated patients-
reported outcomes after surgical fibroid treatment. Myomectomy via laparotomy and hystero-
scopic approach were found to improve quality of life in premenopausal women [9], but
patient-reported outcomes differ between open and laparoscopic surgery and cannot be gener-
alized to laparoscopic procedures [12, 13]. We conducted a comprehensive literature research,
systematically searching MEDLINE (PubMed) using the keywords “laparoscopic myomec-
tomy, quality of life and sexual function”. We found 29 articles, which matched the keywords,
but none of these assessed postoperative quality of life and sexual function in a standardized
way in a collective of exclusively premenopausal patients undergoing laparoscopic myomec-
tomy. A few studies have evaluated patient-reported outcomes of symptomatic fibroid treat-
ment performed using interventional radiology approaches (e.g., embolization, high-intensity
ablation), but premenopausal patients who desire future pregnancy have been excluded in
most cases due to limited experience with and long-term effects of these techniques, which
limits the generalizability of these findings [14–16]. Our study aimed to address this critical
niche by evaluating postoperative quality of life and sexual function in a valid and reproducible
manner using the Female Sexual Function Index (FSFI) and European Quality of Life Five-
Dimension Scale (EQ-5D) in premenopausal women with symptomatic fibroids undergoing
laparoscopic myomectomy.
Material and Methods
All patients who underwent laparoscopic myomectomy between April 2012 and August 2014
at the Department of Gynecology and Obstetrics at a tertiary university center were enrolled
in this prospective observational cohort study. All participants provided written informed con-
sent and ethical approval from the Saarland institutional review board was obtained for this
Patient-Reported Outcomes after Myomectomy
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study (registration number 180/13). The trial was registered in the German Clinical Trials Reg-
ister (DRKS) (trial registration number DRKS00005622). The following inclusion criteria were
applied: 1) premenopausal status at time of surgery, assessed according to World Health Orga-
nization criteria [17]; 2) laparoscopic myomectomy performed without concurrent unilateral
or bilateral adnexectomy; and 3) American Society of Anesthesiologists physical status classifi-
cation of I or II, assessed preoperatively by Anesthesiology. Exclusion criteria were: 1) refusal
to participate in the study; 2) prior treatment with gonadotropin-releasing hormone agonists
or ulipristal acetate or other perioperative hormonal treatment; 3) current endometriosis or
history of surgery to treat endometriosis 4) intra-operatively diagnosed adnexal pathology
requiring uni- or bilateral oophorectomy. Preoperatively, all patients provided medical history
and underwent gynecologic examination and transvaginal ultrasound (Philips CX 50, Philips,
Hamburg/Germany) to document the size, localization and number of fibroids. Basic labora-
tory tests were performed upon admission. As described in detail previously, all surgeries were
performed in the hospital‘s Department of Gynecology under general anesthesia by an experi-
enced consultant or registrar [11, 18]. All patients received perioperative antibiotics (single-
shot cefuroxime (1.5 g i.v.; Fresenius, Bad Homburg/Germany) and metronidazole (0.5 g i.v;
Fresenius, Bad Homburg/Germany) and low-molecular-weight heparin (enoxaparin 40 mg,
s.c. once a day; Sanofi-Aventis, Paris/France) as thromboembolism prophylaxis and indwelling
catheter were used until the first postoperative morning. Laparoscopic myomectomy was per-
formed in the lithotomy position using four ports as described previously [18]: one 10-mm
optic trocar inserted through the umbilicus; two 5-mm working trocars inserted through the
infero-lateral abdominal wall, two fingers’ distance above the iliac crest; and one 15-mm work-
ing trocar in the suprapubic area, two fingers‘distance above the symphysis pubis. The laparo-
scopic technique used in this study has been described in detail elsewhere [18, 19]. A diluted
(1:200.000) epinephrine solution (Xylonest, Astra-Zeneca, Wedel/Germany) was injected into
the serosa and the myometrium overlying the fibroid for vasoconstriction. After vertical inci-
sion of the serosa and myometrium, enucleation was performed. The myometrial defect was
closed with intracorporal interrupted single- or two-layer sutures (Vicryl 1; Ethicon, Noder-
stedt/Germany). Fibroids were morcellated with an electric morcellator (Rotocut G1; Storz,
Tuttlingen/Germany) and extracted through the medial trocar. The duration of surgery (from
umbilical cutaneous incision to closure of all trocar sites), number, position and localization
of fibroids, classified according to the International Federation of Gynecology and Obstetris
(FIGO) system for uterine leiomyomas [20], intraoperative occurrence of adverse events
(defined as iatrogenic injury of the bladder, bowel, ureter, or any major vessel; need for intrao-
perative conversion to laparotomy or abandonment of the intended surgical procedure),
patients‘comorbidities, daily medication and history and number of previous operations
(using the previous surgery score as described by van Evert et al.: calculated as one point per
laparoscopy plus two points per laparotomy (including cesarean sections)) [21], pre- and post-
operative hemoglobin concentrations, duration of postoperative hospitalization, first postoper-
ative day to day of discharge, and surgical complications, according to the Clavien-Dindo
Classification [22] were documented.
Patients were advised to avoid sexual intercourse for six weeks after laparoscopic myomec-
tomy and to avoid pregnancy for six months postoperatively. In cases of opening of the uterine
cavity patients were counseled to undergo a primary cesarean section in case of pregnancy in
order to minimize the risk for uterine rupture. Main outcome measures were patients‘preo-
perative and six-month postoperative sexual function and quality of life. Enrollment, signing
of the consent from, delivery and return of the preoperative questionnaire took place at the
first preoperative visit of the patients at our outpatient department. The timeline between
this first visit and the date of surgery ranged between three to eight weeks. The postoperative
Patient-Reported Outcomes after Myomectomy
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questionnaires were sent to the patients by postal mail six months after the operation. The
patients returned the questionnaires by postal mail within one to six weeks. In order to ensure
confidentiality a study number was assigned to all patients upon registration.
Sexual function and quality of life were assessed using FSFI and EQ-5D. As described previ-
ously, the FSFI is a validated, multidimensional, self-reported instrument for the assessment of
female sexual function [11, 23, 24]. It consists of 19 items evaluating the FSFI lubrication, sex-
ual arousal, orgasm, sexual satisfaction, and pain. The total score (range: 2 (severe sexual dys-
function) to 36 (full sexual function)) is calculated by summing the five domain score and
interpreted by comparison with age- and population-dependent reference values for normal
and impaired sexual function [25] [24]. A FSFI score 26.55 is considered to indicate sexual
dysfunction [25]. The EQ-5D is a standardized, validated instrument used to measure an indi-
vidual’s health status [11, 26]. The questionnaire consists of two parts; the descriptive portion
assesses five dimensions of health-related quality of life (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression) using three levels (no problem, some/moderate
problems, and extreme problems). Using the time trade-off method, an age- and ethnicity-spe-
cific EQ-5D index score (EQ-5D score; range: 1 (full quality of life) to—0.207 (worst health sta-
tus)) was calculated for each patient. The second part of the questionnaire comprises a vertical
visual analog scale (VAS) ranging from optimal health status (100 points) to worst health status
(0 points). Differences in pre- and postoperative FSFI, EQ-5D and VAS scores (FSFI-d, EQ-
5D-d and VAS-d respectively) were determined.
A sample size of at least 55 patients was sought to achieve 80% power to detect a mean
paired difference of 2.0 score points on FSFI changes between baseline and postoperative val-
ues with an estimated 5.0 standard deviation of differences and a significance level (alpha) of
0.05 using a two-sided Wilcoxon test. We inflated the sample size to 115 patients to allow for
drop-outs and incomplete questionnaires. We used descriptive statistics and the Kolmogorov–
Smirnov test to assess normality of FSFI, EQ-5D and VAS score distributions. As the data was
not normally distributed, we used the Wilcoxon signed-rank test for dependent samples to
compare pre- and postoperative values and the Mann–Whitney U-test to assess differences
between groups with FSFI scores 26.55 and>26.45 and differences between FSFI, EQ-5D
and VAS values by main indication for myomectomy. Spearman‘s rank correlation coefficient
was used to assess correlations between the position, localization and number of fibroids and
FSFI, EQ-5D and VAS scores. For pre- and postoperative comparison of patients living in a
relationship McNemar‘s exact test was used. Data are reported as means ± standard deviations,
or as medians (ranges) for variables with non-Gaussian distribution. Data were collected in an
Excel database (Excel 2010; Microsoft Corporation, Redmond, WA/USA), statistical calcula-
tions were performed with SPSS software (Version 19; SPSS Inc., Chicago, IL, USA) and PASS
(Version 12.0.2.; Kaysville, UT/USA) was used for sample size calculation.
Results
During the study period a total of 129 patients underwent laparoscopic myomectomy. Four-
teen patients were excluded; seven did not meet the inclusion criteria, five declined to partici-
pate in the study and two patients were excluded post-operatively due to intra-operatively
diagnosed adnexal pathology requiring subsequent uni- or bilateral oophorectomy. Ninety-
five of 115 study participants, returned questionnaires post-operatively (83% response rate).
Seven patients were excluded due to incomplete questionnaire responses. Thus, the analyses
included a total of 88 premenopausal patients who underwent laparoscopic myomectomy
(Fig 1).
Mean age and BMI at time of operation were 35.4 years (± 5.5) and 25.4 kg/m2 (± 6.4).
Patient-Reported Outcomes after Myomectomy
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66 patients (75%) stated that they had never undergone surgery before and the 22 patients
(25%) who had undergone surgery before had a median previous surgery score of one (range
1–3). 18 patients (20%) had a history of musculoskeletal (seven patients), endocrinologic (five
patients), cardiovascular (two patients), auto-immune (two patients) or ophthalmologic (two
patients) comorbidities and seven patients were on daily medication for these diseases. These
patients‘characteristics were not correlated with pre- or postoperative sexual function or qual-
ity of life.
Main indications for surgery were lower abdominal pain (47.7%), infertility/sterility
(30.7%), abnormal uterine bleeding (14.8%), preoperative symptomatic pelvic mass (4.5%)
and other benign pathologies (2.3%). The mean duration of surgery was 121.5 (± 63.2) minutes
and the mean reduction in hemoglobin was 0.6 (± 0.5) g/dl. A mean number of 2.3 (± 2.1)
fibroids with an average maximum diameter of 52.8 (± 21.8) mm were removed (Table 1).
Sixty-one (69.3%) patients had one or two myomas, 27 (30.7%) patients had three or more
myomas. Regarding the localization of the largest fibroids, 44 (50%) were intramural (FIGO
O-3/O-4), 31 (35.2%) were subserous (FIGO O-5/O-6), 6 (6.8%) were submucosal (FIGO
SM-2), 5 (5.7%) were subserous pedunculated (FIGO O-7) and 2 (2.3%) were broad or round
Fig 1. Flow chart of study design (n = 88).
doi:10.1371/journal.pone.0166659.g001
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ligament fibroids with no relation to the myometrium (FIGO O-8). The rates of posterior,
anterior, fundal and lateral fibroid position were 35.2% (n = 31), 26.1% (n = 23), 26.1%
(n = 23) and 12.6% (n = 11) respectively (Table 1). Preoperative diagnosis of uterine fibroids
was confirmed by postoperative histopathologic examination in all cases. These examinations
revealed no malignant lesion within the study cohort. In two patients, the initial laparoscopic
route was abandoned and myomectomy was performed by laparotomy due to the presence of
extensive adhesions (n = 1) or multiple intramural fibroids (n = 1). In the postoperative course
a total of five complications (5.7% complication rate) were noted. In four patients, these com-
plications were classified as minor (grade I (n = 3) or grade II (n = 1)) complications according
to the Clavien-Dindo system. One major (grade III) complication (requirement for surgical
intervention due to postoperative intraabdominal bleeding) was recorded.
Table 1. Patients‘characteristics and surgical outcomes (n = 88).
Mean SD
Age (years) 35.4 5.5
BMI (kg/m2) 25.4 6.4
Duration of surgery (minutes) 121.5 63.2
Hemoglobin drop (g/dl) 0.6 0.5
Postoperative hospitalization (days) 3.4 1.4
Average diameter of leading fibroid (mm) 52.8 21.8
Number of fibroids removed 2.3 2.1
n %
Main indication for myomectomy
Lower abdominal pain 42 47.7
Infertility/Sterility related to myoma 27 30.7
Abnormal uterine bleeding 13 14.8
Preoperative symptomatic pelvic mass 4 4.5
Other 2 2.3
Number of myomas
< 3 61 69.3
 3 27 30.7
Localization of largest fibroid*
Submucosal with intramural component (FIGO SM-2) 6 6.8
Intramural (FIGO O-3/O-4) 44 50
Subserous (FIGO O-5/O-6) 31 35.2
Subserous pedunculated (FIGO O-7) 5 5.7
Broad and/or round ligament with no relation to myometrium (FIGO O-8) 2 2.3






Grad I-II 4 4.6
Grad III 1 1.1
Grad IV-V - -
*Classification according to the FIGO classification system of uterine leimyomas (16)
** Classified according to the Clavien-Dindo classification for surgical complications (17)
doi:10.1371/journal.pone.0166659.t001
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The percentages of women living in a relationship did not differ significantly between the
pre- (86.4%) and postoperative (88.4%) status (p = 1). Median preoperative FSFI, EQ-5D and
VAS scores were 21.1 (5.2–33.5), 0.9 (0.2–1) and 70 (15–100) respectively. Median postopera-
tive scores 28 (18.7–35.2), 1 (0.6–1) and 90 (50–100) respectively, were significantly higher
than preoperative scores (p<0.001; Table 2).
Postoperative FSFI domain scores (desire, lubrication, arousal, orgasm, satisfaction,
pain) were also significantly higher than preoperative scores (p<0.001; Table 2). Patients
with normal preoperative FSFI scores ( 26.55; n = 16) [27] showed no significant increase
in postoperative FSFI (p = 0.45), EQ-5D (p = 0.09) or VAS score (p = 0.55). Regarding the
main indication for myomectomy, patients treated for lower abdominal pain showed the
lowest preoperative FSFI scores and the highest increase in FSFI-values compared to
patients treated for other indications (16.6 (5.2–20.5) vs. 24.7 (20.6–33.5) p<0.001; 8.2 (1–
23.2) vs. 4.7 (0–10.6) p<0.001. With median preoperative FSFI scores of 23.1 (21.6–23.7)
and 25.4 (20.6–30.6) patients treated for abnormal uterine bleeding and infertility also
showed an impaired preoperative sexual function (FSFI < 26.55). Both groups had a signifi-
cant increase in postoperative FSFI scores (28.9 (24.5–33.6) p<0.001; 29.9 (25–35.2)
p<0.001). Looking at EQ-5D and VAS values there were no significant differences between
the five indication groups.
FSFI, EQ-5D and VAS scores were not correlated with the position or localization of the
largest fibroid or the total number of fibroids (p>0.05). Regarding the differences between
postoperative and preoperative scores, subserous pedunculated (FIGO O-7) myomas showed
significant lower FSFI- (FSFI-d) differences and significantly lower differences in the FSFI sub-
domain pain (pain-d) when compared with other localizations and subserous (FIGO O-5/O-
6) myomas were associated with significantly higher values in these two categories (p<0.05;
Table 3).
Patients in whom conversion to laparotomy was performed (n = 2) or a major postoperative
complication was noted (n = 1), all (n = 3) completed the questionnaires post-operatively and
postoperative FSFI, EQ-5D, and VAS scores did not differ significantly from those of the rest
of the cohort.
Table 2. Comparisons of pre- and postoperative FSFI, EQ-5D, VAS scores and FSFI. domains (n = 88).
Preoperative Postoperative
Median Range Median Range
Main scores
FSFI 21.1 5.2–33.5 28* 18.7–35.2
EQ-5D 0.9 0.2–1 1* 0.6–1
VAS 70 15–100 90* 50–100
FSFI domains
Desire 3 0.6–6 4* 1.2–6
Arousal 3.2 0–5.7 4.5* 1.2–6
Lubrication 4 0.6–6 5* 0.9–6
Orgasmn 3.6 0–6 4.4* 1.2–6
Satisfaction 3.4 0.4–6 4.8* 1.2–6
Pain 4.6 0–6 6* 2–6
* p<0.001 for comparison of pre- and postoperative FSFI, EQ-5D, VAS scores and FSFI domains, Wilcoxon signed-rank test for dependent samples was
used to compare pre- and postoperative values
doi:10.1371/journal.pone.0166659.t002
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Discussion
This study was designed to evaluate quality of life and sexual function following laparoscopic
myomectomy in a valid and reproducible manner. To address this methodological challenge,
we assessed the impacts of this treatment in a representative cohort of premenopausal patients
with symptomatic fibroids and predominantly impaired preoperative sexual function present-
ing at a tertiary university center. Laparoscopic myomectomy seemed to have positive short-
term effects on postoperative quality of life and sexual function in this cohort. In a subgroup
analysis we found patients with impaired preoperative sexual function to benefit most from
the procedure.
Two recent studies have used similar designs to evaluate postoperative quality of life and
sexual function in patients undergoing abdominal myomectomy for symptomatic fibroids.
Dilek and colleagues evaluated the impact of myomectomy via laparotomy on women‘s quality
of life using the Short Form Health Survey and reported postoperative improvement in “pain”
“vitality” and “general health” but no improvement in “physical function” or “mental health”
scores [9]. Similarly Ertunc and colleagues assessed the effect of myomectomy via laparotomy
on patients‘ sexual function using the FSFI score [8]. They found significant increases in post-
operative total FSFI and in the FSFI subdomain pain scores relative to preoperative scores.
Our findings are in partial agreement with the results of these studies. However we found sig-
nificant increases in all quality of life aspects and all FSFI subdomains. These discrepancies
may be related to differences in surgical approach. In comparison with laparoscopic surgery,
open surgery is associated with higher postoperative wound pain levels and increased time
until resumption of normal activities of daily life [28]. Some authors have suggested that higher
postoperative wound pain levels and adhesion formation result in long-term impairment
of quality of life after laparotomic procedures [29]. Griffin and colleagues observed lower
postoperative wound pain levels and an accelerated return to work in women who underwent
laparoscopic-robotic myomectomy compared with those who underwent myomectomy via
laparotomy [28]. In addition to the clinical superiority of this surgical technique, our findings
Table 3. Correlation of pain- and FSFI-score differences with number, localization and position of fibroid (n = 88).
Pain-d FSFI-d
Median Range p Median Range p
Number of myomas
< 3 1.2 0–6 0.1 5.6 0–23 0.3
 3 1.2 0–3.2 0.3 4.9 0–20 0.9
Localization of largest fibroid
Submucosal with intramuralcomponent (FIGO SM-2) 4.9 1–8 0.4 1.2 0–2.8 0.5
Intramural (FIGO O-3/O-4) 6.5 1–23 0.3 1.6 0–5.6 0.4
Subserous (FIGO O-5/O-6) 4.5 0–14 < 0.05 1.2 0–6 0.04
Subserous pedunculated(FIGO O-7) 14.5 5–20 0.01 3.2 1.2–6 0.01
Broad and/or round ligamentwith no relation tomyometrium (FIGO O-8) 7.9 5–11 0.7 1.2 0.8–1.6 0.74
Position of largest fibroid
Anterior 6.4 1–20 0.5 1.4 0.8–6 0.7
Posterior 5.2 0–19 0.7 1.2 0–6 0.6
Lateral 6.2 1–17 0.7 1.2 0–5.6 0.2
Fundal 5.1 0–23 0.5 0.8 0–3.2 0.5
-d: differences between postoperative and preoperative pain- and FSFI-scores; Spearman‘s rank correlation coefficient was used to assess correlations
between the position, localization and number of fibroids and score differences
doi:10.1371/journal.pone.0166659.t003
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indicate that minimal-invasive myomectomy may also improve patient-reported outcomes rel-
ative to open myomectomy.
Previous studies have shown that fibroid-related symptoms and impaired quality of life and
sexual function are not correlated with the number, position or localization of fibroids [30].
We found greater improvement in sexual function among women with subserous and less
improvement in those with subserous pedunculated myomas. These findings may not be
directly related to fibroid localization, but may be a result of differences in postoperative symp-
tom relief, as reflected by FSFI subdomain pain-differences values. These values were greater
in patients with subserous and smaller in those with subserous pedunculated fibroids.
Several studies have provided support for the hypothesis that improved post-myomectomy
quality of life and sexual function are derived mostly from symptom relief achieved by the sur-
gery [31]. Wang and colleagues demonstrated that myomectomy normalized quality of life by
improving symptoms in patients with symptomatic fibroids [32]. This assumption is also sup-
ported by the lack of significant changes in FSFI and EQ-5D scores in patients with normal
preoperative FSFI scores in the present study. The therapeutic effect achieved by myomectomy
seems to manifest only in patients with impaired preoperative sexual function and might origi-
nate in somatic symptom relief. Correspondingly we found the highest impairment in sexual
function preoperatively and the highest effect of myomectomy in patients undergoing surgery
for abdominal pain as main indication. However patients undergoing laparoscopic myomec-
tomy for uterine bleeding disorders and infertility also presented with impaired preoperative
sexual function and obtained significant improvement in sexual function by myomectomy.
According to the recent U. S. Food and Drug Administration safety warning about the use of
laparoscopic power morcellation, laparoscopic myomectomy should be conducted only after
careful benefit-risk evaluation and in patients for whom it is considered the best therapeutic
option [33]. In this context preoperative evaluation using the FSFI and EQ-5D might be of value
in predicting treatment success and selecting patients most likely to benefit from this treatment.
This study showed that laparoscopic myomectomy in premenopausal patients with symp-
tomatic fibroids might significantly affect patient-reported outcomes within a short-term fol-
low-up period. Several authors have documented increased sexual function and quality of life
following surgical treatment of benign uterine pathologies, but these differences were much
smaller than observed in this study [8, 11]. A possible explanation for these differences in find-
ings could be the fact that we evaluated quality of life and sexual function six months after lapa-
roscopic myomectomy. These short-term results cannot be generalized to mid- and long-term
outcomes. Fibroid recurrence and persistent postoperative infertility can affect quality of life
and sexual function in the long term, thereby; altering the long-term outcomes of initially suc-
cessful treatment [19, 34]. We did not assess fibroid recurrence or fertility rates in this study
because valid information could not be obtained within the follow-up period. Further investi-
gations are needed to evaluate the long-term effects of laparoscopic myomectomy on patient-
reported outcomes.
In a minor, yet considerable percentage, (3.4%) of patients in our study the postoperative
course was altered substantially by intraoperative conversion to laparotomy or the occurrence
of major postoperative complications. Although these patients’ postoperative FSFI, EQ-5D
and VAS scores did not differ from those of the rest of the study population, adverse events
related to laparoscopic fibroid treatment might have considerable negative impacts on postop-
erative quality of life and sexual function in individual cases. This factor should be considered
in the preoperative counseling of patients suffering from symptomatic fibroids.
A limitation of the study is the use of an open-series design with no control group. Spies and
colleagues noted significant improvement in the quality of life of patients with symptomatic
fibroids following radiologic interventional or surgical (predominantly via laparotomy)
Patient-Reported Outcomes after Myomectomy
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treatment, in contrast to the lack of positive changes during the study period an untreated con-
trol group [35]. In light of these findings, we found it ethically questionable to assign a portion
of patients presenting at our hospital for the treatment of symptomatic fibroids to a non-inter-
ventional control group for the purposes of this study. Due to this methodological challenge
the possible contributions of additional factors other than the ones assessed to the observed
postoperative changes in patient-reported outcomes cannot be excluded.
This study does not provide a comparison between laparoscopic and open myomectomy
and to the best of our knowledge there is no currently available data comparing these surgical
approaches in terms of sexual function and quality of life. In comparison to the two studies
cited before, which assessed sexual function and quality of life after open myomectomy,
patients in our cohort showed better outcomes (8, 9). This result might indicate an advantage
for the minimal-invasive approach over open myomectomy in terms of these patient-reported
outcomes. However further research will be needed in order to sufficiently answer this ques-
tion. Patients’ preoperative sexual function and quality of life were assessed in close temporal
relation to the decision to undergo surgical treatment and to the date of surgery itself. This
constitutes a potential limitation with regards to the external validity of our data, since the pre-
operative period is loaded with emotional issues that might interfere “per se” on quality of life
and sexual function. Assessment of quality of life and sexual function in our patients may have
been affected by patients’ potential anxiety originating from forthcoming intervention and
on top of that psychopathologic issues cannot be excluded. In our study sample, we did not
observe a significant change in pre- and postoperative values for the EQ5-D subcategory anxi-
ety/depression, indicating a potential systematic bias due to patients’ anxiety caused by the
impending surgery. However, we acknowledge, that such preoperative anxiety could have
affected preoperative FSFI and EQ5-D values in some of our study patients.
Another limitation might be constituted by the special nature of our cohort. Almost one
third of our patients underwent laparoscopic myomectomy with “infertility” as main indica-
tion, which is a relative weak indication and on the contrary, only 15% underwent laparo-
scopic myomectomy for abnormal uterine bleeding/menorrhagia, which is instead considered
one of the major indications to fibroid surgery. In our opinion a possible explanations for this
“untypical” distribution of fibroid-related symptoms could be that our study collective con-
sisted exclusively of premenopausal patients with a mean age of 35.4 years. In this premeno-
pausal cohort indications for myomectomy and presenting symptoms might be different
compared to peri- or postmenopausal cohorts as described in other publications [36].
Impaired sexual function is generally not regarded as an indication for surgical treatment
of otherwise asymptomatic uterine fibroids. However, given the significant postoperative
improvement in sexual function observed in the majority of study participants, the question
whether poor sexual function should be included as an indication for myomectomy should be
addressed in future research.
In summary we found that premenopausal women undergoing laparoscopic myomectomy
for symptomatic fibroids might have statistical significant short-term improvements in quality
of life and sexual function. Patients with impaired preoperative sexual function seemed to ben-
efit most from surgery. These findings might help to improve selecting patients for laparo-
scopic myomectomy. However long-term outcomes of laparoscopic myomectomy have to be
further evaluated.
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